Cathie Wood's Buys And Rumors Aside, Here's Why Crispr Therapeutics Is A Strong Buy
2025-12-04 10:29:50 ET
Crispr Therapeutics AG ( CRSP ) was founded in 2013 and is based in Zug, Switzerland. It is the market leader in transformative therapies incorporating CRISPR/Cas9 technology, solidifying its position after receiving approval by the FDA (Dec 2023) & EMA (Feb 2024) for Casgevy to treat Transfusion-dependent Beta Thalassemia ((TDT)) and Sickle Cell Disease ((SCD)). This was the world’s first approved treatment incorporating CRISPR/Cas9 technology, which they co-developed and commercialized in partnership with the biotech giant Vertex Pharmaceuticals ( VRTX ). Vertex retains a 60/40 revenue split with Crispr for this treatment and has the option to co-develop several others going forward....
Read the full article on Seeking Alpha
For further details see:
Cathie Wood's Buys And Rumors Aside, Here's Why Crispr Therapeutics Is A Strong Buy
NASDAQ: NVS
NVS Trading
-1.36% G/L:
$143.37 Last:
954,184 Volume:
$144.01 Open:
